Effect of linagliptin vs Placebo on major cardiovascular events in adults with type 2 Diabetes and high cardiovascular and renal risk The CARMELINA Randomized Clinical Trial

Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective To evaluate the effect of li...

Full description

Autores:

Rosenstock, Julio
Perkovic, Vlado
Johansen, Odd Erik
Cooper, Mark E.
Kahn, Steven E.
Marx, Nikolaus
Alexander, John H.
Pencina, Michael
Toto, Robert D.
Wanner, Christoph
Zinman, Bernard
Juergen Woerle, Hans
Baanstra, David
Pfarr, Egon
Schnaidt, Sven
Meinicke, Thomas
George, Jyothis T.
von Eynatten, Maximilian
McGuire, Darren K.
Aroca-Martínez, Gustavo

Tipo de recurso:

Fecha de publicación:

2019

Institución:

Universidad Simón Bolívar

Repositorio:

Repositorio Digital USB

Idioma:

eng

OAI Identifier:

oai:bonga.unisimon.edu.co:20.500.12442/15719

Acceso en línea:

https://hdl.handle.net/20.500.12442/15719
https://www.webofscience.com/wos/woscc/full-record/WOS:000455606000016

Palabra clave:

HEART-FAILURE
KIDNEY-DISEASE
GFR DECLINE
END-POINT
OUTCOMES
SITAGLIPTIN
DEATH
SAXAGLIPTIN
MORTALITY
CKD

Rights

closedAccess

License

Attribution-NonCommercial-NoDerivs 3.0 United States